Suvizumab
Based on 1 Customer Validation
Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection.
For research use only. We do not sell to patients.
- Purity: ≥99.0%
- CAS No.: 914257-21-9
- Molecular Weight:146.38 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG1 kappa
Virus
|
HIV-1 |
HIV-189.6 0.2 μg/mL (IC50) |
HIV-1MN 0.1 μg/mL (IC50) |
HIV-1SF2 1.0 μg/mL (IC50) |
Suvizumab shows highly resistant to pseudotyped virus with the G314E mutation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Suvizumab (45 mg/kg; i.v.; once a week for 2 months) reduces the loss of CD4 T cells in lymphoid tissue in male cynomolgus monkeys infected with simian/human immunodeficiency virus-C2/1[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized Envelope glycoprotein gp120 Protein, HIV-1 can bind Suvizumab. The EC50 for this effect is 9.057 ng/mL.
Chemical Information
-
CAS No. 914257-21-9
-
Appearance Liquid
-
Molecular Weight 146.38 kDa
-
Color Colorless to light yellow
-
SMILES
[Suvizumab]
-
Synonyms
KD-247
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Matsushita S, et al. Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1. AIDS. 2015 Feb 20;29(4):453-62. [Content Brief]
[2]. Eda Y, et al. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J Virol. 2006 Jun;80(11):5563-70. [Content Brief]
[3]. Yoshimura K, et al. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS. 2006 Oct 24;20(16):2065-73. [Content Brief]
[4]. Murakami T, et al. Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue. AIDS. 2009 Jul 31;23(12):1485-94. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz